Navigation Links
NewCardio Completes $2.9 Million Private Placement
Date:9/18/2009

SANTA CLARA, Calif., Sept. 18 /PRNewswire-FirstCall/ -- NewCardio, Inc., (OTC Bulletin Board: NWCI) a cardiac diagnostic technology provider, today announced that it closed a private placement financing with institutional and other accredited investors, including members of NewCardio's management team and board of directors, who purchased over half of the offering. Gross proceeds of approximately $2.9 million were generated through the issuance of approximately 2,900 shares of a new Series C Convertible Preferred Stock at $1,000 per share and convertible into approximately 2.9 million common shares, together with approximately 2.9 million common stock purchase warrants having an exercise price per share of $1.20. The Benchmark Company LLC served as the placement agent, who engaged Hallmark Investments as a selected dealer in this transaction.

Branislav Vajdic, PhD, NewCardio's Chief Executive Officer, commented, "The successful completion of this transaction, despite the difficult economic conditions and the challenges small companies face in securing additional growth capital, demonstrates the confidence management, our board of directors, and these accredited investors have in NewCardio's platform technology and the opportunities in front of us."

The securities issued in the private placement are not registered under the United States Securities Act of 1933 or the securities laws of any other jurisdiction. Accordingly, these securities may not be sold by investors in the United States, except pursuant to an effective registration statement or an applicable exemption from the registration requirements. Transfer and other disposition of the Series C Convertible Preferred Stock and warrants are also subject to certain limitations that continue during months 7-12 after issuance, based on the trading price and volume of the Company's publicly traded common shares. For more detailed information on this financing, see the Company's Current Report on Form 8-K which will be filed with the Securities and Exchange Commission on or about September 15, 2009.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any security and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful.

In the last 90 days, NewCardio has experienced a series of successes in adoption by key industry players in the life science market, including a top-five largest pharmaceutical company. The Company has entered into three master services agreements for the integration of QTinno(TM) into product and service offerings of two top-five largest Contract Research Organizations (CROs) as well as a cardiac safety and clinical trials service provider. Management expects to formalize additional agreements as the industry begins to realize the benefits and potential of QTinno(TM) in advancing the current cardiac safety analysis approaches. This expectation is supported by positive feedback from a recent presentation of the QTinno(TM) technology and validation results with the FDA.

About NewCardio, Inc.

NewCardio is a cardiac diagnostic and services company focused on the development of a proprietary platform technology to provide higher accuracy to, and increase the value of, the standard 12-lead electrocardiogram (ECG). NewCardio's development-stage software and hardware products and services are intended to improve the diagnosis and monitoring of cardiovascular disease (CVD), as well as cardiac safety assessment of drugs under development. NewCardio's three-dimensional ECG platform is designed to reduce the time and expense involved in assessing cardiac status while increasing the ability to diagnose clinically significant conditions which were previously difficult to detect. For more information, visit www.newcardio.com.

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates and projections about our business based on currently available information and assumptions made by management. Although we believe that the assumptions on which the forward-looking statements contained herein are based are reasonable, any of those assumptions could prove to be inaccurate given the inherent uncertainties as to the occurrence or nonoccurrence of future events. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict. Therefore, actual outcomes and results may, and are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors, including the potential risks and uncertainties set forth in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2008 and relate to our business plan, our business strategy, development of our proprietary technology platform and our products, timing of such development, timing and results of clinical trials, level and timing of FDA regulatory clearance or review, market acceptance of our products, protection of our intellectual property, implementation of our strategic, operating and people initiatives, benefits to be derived from personnel and directors, ability to commercialize our products, our assumptions regarding cash flow from operations and cash on-hand, the amount and timing of operating costs and capital expenditures relating to the expansion of our business, operations and infrastructure, implementation of marketing programs, our key agreements and strategic alliances, our ability to obtain additional capital as, and when, needed, and on acceptable terms and general economic conditions specific to our industry, any of which could impact sales, costs and expenses and/or planned strategies and timing. We assume no obligation to, and do not currently intend to, update these forward-looking statements.

To join our email distribution please click this link: http://www.b2i.us/irpass.asp?BzID=1645&to=ea&s=0

    Investor Contact:
    Hayden IR
    Jeff Stanlis, Partner and VP of Communications
    (602) 476-1821
    jeff@haydenir.com


'/>"/>
SOURCE NewCardio, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Dr. Dorin Panescu, NewCardios Chief Technology Officer, Awarded Professional Career Achievement Award by the IEEE Engineering in Medicine and Biology Society
2. NewCardio Announces Master Services Agreement With Top-Three Contract Research Organization
3. Top-Five Global Pharmaceutical Company Names NewCardio as its Provider of Automated Thorough QT Solution
4. NewCardio to Present at CapStones Third Annual Small-Cap Investor Conference July 30
5. NewCardio Medical and Technology Team Presents Two Abstracts at Heart Rhythm Society Conference
6. NewCardio to Introduce Technology at Heart Rhythm Society Conference
7. NewCardio Leadership to Make Two Presentations at Drug Information Association Drug Safety Conference
8. NewCardio Elects Michael E. Hanson to Board of Directors
9. UPDATE: NewCardio Leadership to Present Clinical Data of Fully Automated QTinno(TM) Study at American College of Cardiology Annual Meeting
10. NewCardio Leadership to Present Clinical Data of Fully Automated QTinno(TM) Study at American College of Cardiology Annual Meeting
11. NewCardio to Present at OneMedForum 2009: Disrupters and Drivers on January 13 in San Francisco
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... ... January 16, 2017 , ... St. Louisans are well-aware of the following facts at present:, ... influenza shot seems to be having no effect on keeping this particularly bad strain of ... people around are coughing, sneezing, or sniffling , These facts are well-known ...
(Date:1/16/2017)... ... January 16, 2017 , ... Board-certified oculoplastic surgeon Dr. Mehryar ... official journal of The American Society for Aesthetic Plastic Surgery, in which he ... designed to correct drooping, retracted lower eyelids, which usually result from genetics, injury, ...
(Date:1/16/2017)... ... , ... One thing common to all types of cancer is that it’s ... The money spent screening for and treating cancer in the United States is estimated ... more than in any other country that has an advanced healthcare system, sometimes spending ...
(Date:1/16/2017)... , ... January 16, 2017 , ... ... been appointed Chief Executive Officer of the medical device company, effective immediately. , ... Robert Storey. “Kevin has a strong track record in medical device market ...
(Date:1/15/2017)... New York, NY (PRWEB) , ... January 15, 2017 , ... ... growing strategic accounts in the United States for the asthma & allergy friendly mark. ... of America to independently test and identify consumer products to be more suitable for ...
Breaking Medicine News(10 mins):
(Date:1/16/2017)... -- The global pacemaker market is expected to reach ... report by Grand View Research, Inc. The heightening prevalence ... coverage is a key driving factor governing the growth ... devices are supporting the expansion of this vertical. ... growth rendering driver for this market. A death estimate ...
(Date:1/16/2017)... , Jan. 16, 2017 Derek H. ... Law Firm, was recently appointed Liaison Counsel in ... for all Xarelto cases. In this role, Potts was ... and will actively assist the Court and Co Lead ... Milstein Adelman Jackson Fairchild & Wade ...
(Date:1/16/2017)...  Harrington Discovery Institute at University Hospitals in ... of The Harrington Project for Discovery & Development ... in collaboration with Alzheimer,s Drug Discovery Foundation (ADDF), ... Harrington Discovery Institute collaborations are ... into new medicines that will improve human health, ...
Breaking Medicine Technology: